Status:
TERMINATED
Dupilumab Phase 4 Study
Lead Sponsor:
Northwestern University
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
12+ years
Brief Summary
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe ...
Detailed Description
The investigators will conduct a prospective, longitudinal, non-interventional and observational sub-study of patients receiving dupilumab as normal standard-of-care treatment to assess the efficacy (...
Eligibility Criteria
Inclusion
- Individuals aged 18 and over who have been diagnosed with Atopic Dermatitis and are using dupilumab therapy as part of standard of care.
- Parents of adolescents ages 12 to 17 who have been diagnosed with Atopic Dermatitis and are receiving dupilumab off-label for the management of AD.
Exclusion
- Patients not on dupilumab
- Those who do not comply with the study requirements
- Those who do not provide informed consent
Key Trial Info
Start Date :
October 16 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2019
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT03411837
Start Date
October 16 2017
End Date
August 31 2019
Last Update
October 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University Department of Dermatology
Chicago, Illinois, United States, 60611